ROLE OF LIPOPHILICITY IN THE INVITRO ANTITUMOR-ACTIVITY OF A SERIES OF NEW MITOSENE COMPOUNDS

被引:0
|
作者
MALIEPAARD, M [1 ]
DEMOL, NJ [1 ]
JANSSEN, LHM [1 ]
VANDERNEUT, W [1 ]
VERBOOM, W [1 ]
REINHOUDT, DN [1 ]
机构
[1] TWENTE UNIV TECHNOL,ORGAN CHEM LAB,7500 AE ENSCHEDE,NETHERLANDS
来源
ANTI-CANCER DRUG DESIGN | 1992年 / 7卷 / 05期
关键词
MITOSENE; ANTITUMOR ACTIVITY; QSAR; LOG-P; HALF-WAVE REDUCTION POTENTIAL;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The antitumour activity of a series of mitosene compounds in various in vitro tumour models was evaluated in terms of physico-chemical parameters. Lipophilicity, measured as log P, seemed to be important for in vitro antitumour activity in three different cell lines. The in vitro activity of this series of mitosenes in an A204 and a L1210 cell line demonstrated a clear bilinear dependence on log P with optimal activity at log P values of 2.8 and 3.3 respectively. Compounds not able to be activated to bifunctional alkylating species did not fit into this correlation. Although mitosenes have to be activated reductively to alkylating species, no correlation was found between the half-wave reduction potential (E1/2) and the in vitro activity. This lack of correlation may be caused by the relatively small range of E1/2-values within this series of mitosene compounds. Our results indicate that penetration of the antitumour mitosenes into the cell and the site of activation is an important process that leads to antitumour activity and that within the range of compounds studied the structural variations are less important for bioreductive activation.
引用
收藏
页码:415 / 425
页数:11
相关论文
共 50 条
  • [1] ANTITUMOR-ACTIVITY IN THE ACRIDINE SERIES
    SMOLDERS, RR
    ATASSI, G
    VOGLET, N
    WAEFELAER, A
    JOURNAL DE PHARMACIE DE BELGIQUE, 1989, 44 (01) : 11 - 16
  • [2] ANTITUMOR-ACTIVITY OF VANADIUM COMPOUNDS
    DJORDJEVIC, C
    METAL IONS IN BIOLOGICAL SYSTEMS, VOL 31, 1995, 31 : 595 - 616
  • [3] ANTITUMOR-ACTIVITY OF TREWIASINE INVITRO AND INVIVO
    YANG, JL
    SHEN, ZM
    LU, LJ
    HAN, JX
    XU, CH
    LI, BJ
    ACTA PHARMACOLOGICA SINICA, 1988, 9 (06): : 508 - 511
  • [4] INVITRO ANTITUMOR-ACTIVITY OF 2 ISOMERIC CYCLOPALLADIATED COMPOUNDS DERIVED FROM BENZOYLBENZYLIDENIMINES
    NAVARRORANNINGER, C
    LOPEZSOLERA, I
    PEREZ, JM
    MASAGUER, JR
    ALONSO, C
    APPLIED ORGANOMETALLIC CHEMISTRY, 1993, 7 (01) : 57 - 61
  • [5] ANTITUMOR-ACTIVITY OF LIPOSOMAL ACLARUBICIN INVITRO AND INVIVO
    VYADRO, MM
    NAVASHIN, SM
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1991, 112 (11) : 1634 - 1636
  • [6] ANTITUMOR-ACTIVITY OF DERIVATIVES OF NEPLANOCIN A INVIVO AND INVITRO
    HOSHI, A
    YOSHIDA, M
    IIGO, M
    TOKUZEN, R
    FUKUKAWA, K
    UEDA, T
    JOURNAL OF PHARMACOBIO-DYNAMICS, 1986, 9 (02): : 202 - 206
  • [7] ANTITUMOR-ACTIVITY AND ANTIINFLAMMATORY ACTION OF ORGANOTIN COMPOUNDS
    ARAKAWA, Y
    ABE, T
    YU, TH
    WADA, O
    JOURNAL OF PHARMACOBIO-DYNAMICS, 1987, 10 (01): : S2 - S2
  • [8] ANTITUMOR-ACTIVITY OF CHEMICAL MODIFIED NATURAL COMPOUNDS
    DEOLIVEIRA, MM
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1991, 86 : 61 - 65
  • [9] GENOTOXICITY AS ORIGIN OF THE ANTITUMOR-ACTIVITY OF PLATINUM COMPOUNDS
    FICHTINGERSCHEPMAN, AMJ
    ARCHIVES OF TOXICOLOGY, 1993, 67 (10) : 47 - 50
  • [10] ANTITUMOR-ACTIVITY OF NOVEL AILANTHONE DERIVATIVES INVITRO AND INVIVO
    KATO, T
    SUZUMURA, Y
    FUKUSHIMA, M
    HONDA, T
    NAKANISHI, T
    NOGUCHI, T
    ANTICANCER RESEARCH, 1988, 8 (04) : 573 - 580